🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Asian Stocks Up Over Progress on Biden Transition, COVID-19 Vaccine

Published 11/23/2020, 10:39 PM
Updated 11/23/2020, 10:42 PM
© Reuters.
AXJO
-
JP225
-
HK50
-
AZN
-
PFE
-
LCO
-
NWE
-
KS11
-
SSEC
-
SZI
-
MRNA
-

By Gina Lee

Investing.com – Asia Pacific stocks were mostly up on Tuesday morning, as clarity over the U.S. presidential elections finally begins to emerge almost a month after votes were cast on Nov. 3.

Japan’s Nikkei 225 rose 2.83% by 11:36 PM ET (3:36 AM GMT). South Korea’s KOSPI gained 0.90%, with the Bank of Korea due to hand down its policy decision on Thursday.

In Australia, the ASX 200 rose 1.15% and Hong Kong’s Hang Seng Index edged up 0.12%. Chief Executive Carrie Lam is due to deliver her annual policy address on Wednesday, as the city battles a fourth wave of COVID-19 cases.

China’s Shanghai Composite inched down 0.07% and the SZSE Component fell 0.36%. U.S.-China tensions are up over reports that U.S. President Donald Trump’s administration is pushing for fresh, hardline measures against China.

Joe Biden was acknowledged as the apparent winner of the election via a letter from General Services Administration head Emily Murphy on Monday. The letter also said that Biden could formally begin the transition process, which includes access to current agency officials, briefing books, and funding as well as other government resources totaling around $6 million.

Trump also made the first steps towards conceding to the election results, tweeting that his team have been informed to “do what needs to be done with regards to initial protocols.’ However, he is still looking to pursue legal action over the results.

Biden has also started hinting at his cabinet appointments and is likely to tap former Federal Reserve Chairman Janet Yellen as Secretary of the Treasury.

Adding to the positivity was the latest positive news on the COVID-19 vaccine front, after Pfizer Inc (NYSE:PFE) and Moderna Inc (NASDAQ:MRNA) announced positive news about their respective candidates during the previous week.

AstraZeneca PLC (LON:AZN), alongside the University of Oxford, reported on Monday that its candidate, AZD122, met its primary endpoint in clinical trials that took place in the U.K and Brazil. The data will now be submitted to authorities globally for conditional or early approvals.

“Traders are still buying into vaccine news clearance, as the end of the pandemic becomes imaginable. Recent U.S. data restored a bit of confidence that the economy is holding up, despite surging COVID-19 infections and a painful lack of fresh fiscal stimulus,” IG Australia market analyst Kyle Rodda told Reuters.

“And the news of Yellen’s possible nomination to the role of U.S. Treasury Secretary potentially puts a very Fed-friendly uber-dove at the reins of fiscal policy,” Rodda added.

Investors are also rekindling hope that Congress will reach a consensus over the latest stimulus measures as the number of global COVID-19 cases continues to rise.

“Having that end date on the calendar, with what looks like possibly three effective vaccines defines the bottom,” Brent Schutte, Northwestern (NASDAQ:NWE) Mutual Wealth Management Chief Investment Strategist, said on Bloomberg TV. “I think investors will come in and buy the dip, and I do think you will continue to have the rotation to those value names, small-cap names, things that are leveraged to the economic cycle.”

The U.S. is due to release a slew of data, including for jobless claims and GDP, on Wednesday ahead of the Thanksgiving holiday. The Fed will release the minutes from its most recent Federal Open Market Committee meeting on the same day. Data released on Monday showed that the U.S. manufacturing Purchasing Managers Index (PMI) rose to 56.7 in November, above the 53 in forecasts prepared by Investing.com and October's 53.4 reading. The services PMI also exceeded expectations, rising to 57.7 in November.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.